Latest Regulatory Filings News

Savannah Goldfields Limited has explained the late filing of a director’s interest notice, attributing it to an oversight during an entitlement offer. The company affirms its compliance processes remain robust despite the delay.

Black Dragon Gold has withdrawn its application to classify the Salave Gold Project as a Project of Strategic Interest in Asturias, Spain, planning a stronger resubmission backed by legal clarity and community support.

Locate Technologies has dispatched its Scheme Booklet to shareholders, outlining the proposed acquisition by Locate NZ and urging a vote in favour at the upcoming virtual meeting.

Merino & Co. initiates a new chapter with leadership changes and a strategic partnership to enter China’s premium apparel market, while investing heavily in growth during Q1 FY26.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

BPH Energy’s September quarter report highlights pivotal developments across its investees, from a critical judicial review in offshore petroleum to breakthroughs in AI medical devices and clean hydrogen production.

Netlinkz Limited reports steady customer receipts and strategic investments in its Securelink joint venture, while preparing for an ASX relisting and a rebrand to Securelink Networks Ltd.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.